Nilemdo and Nustendi Win Funding In England For High Cholesterol
NICE Is Also Developing Guidance For Novartis’s Cholesterol-Lowering Leqvio
Executive Summary
Around 70,000 adults in England with primary hypercholesterolemia or mixed dyslipidemia will have access to the bempedoic acid ACL inhibitors from Esperion/Daiichi Sankyo.